Medical marijuana firm Aurora Cannabis Inc. has announced a new disclosure process for its quality control data, which it says will assure clients of the purity of its products. [...]
An independent lab in British Columbia says medical marijuana from CanniMed Therapeutics in Saskatoon is free of 56 known pesticides and fungicides. [...]
Longtime landlord Darryl Spencer was left scrambling for insurance after discovering a tenant was growing dozens of medical marijuana plants inside and outside his rental house. [...]
The new owner of a company caught up in the pesticide pot recall is trying to win back customer confidence. [...]
Health Canada says it will begin random testing of medical marijuana products to check for the presence of banned pesticides after contaminated products led to reports of illnesses and the possibility of a class action lawsuit. [...]
A human rights board has determined a Nova Scotia man's prescribed medical marijuana must be covered by his employee insurance plan, a ruling that advocates say will likely have impact nationwide. [...]
The image of the lazy pot-smoker remains one of the most prevailing stigmas about medical cannabis users. [...]
Veterans Affairs is dramatically scaling back the quantity of medical marijuana it will cover for veterans, to three grams a day from 10 grams. [...]
A Halifax woman says she was diagnosed with cannabinoid hyperemesis syndrome after vomiting every day for eight months straight, a symptom that only ended when she gave up medical marijuana. [...]
Canada's largest pharmacy chain has formally applied to be a distributor of medical marijuana. [...]
NO MEDICAL VALUE? US GOVT HAS BEEN FUNDING THIS ISRAELI CANNABIS RESEARCHER FOR 50 YEARS
[9/25/16] JUSTIN GARDNER– As many Americans approach November 4 with a sense of dread, facing the fact that either Donald Trump or Hillary Clinton will be the next president, much more hopeful things will be going on that day. Residents in at least nine states will be voting on ballot initiatives to legalize recreational or medical cannabis use.
Considering the tide of public opinion in favor of legalization, we can expect that most, if not all, of these states will vote for freedom and access to a wondrous medicinal plant. Even the power of Big Pharma, which is pouring money into campaigns to derail legalization efforts since medical cannabis threatens their profits, might be no match for the mass awakening.
For the most part it’s up to the states to lead the way, since federal government appears to be firmly stuck in prohibition. The DEA, which preys on the populace through the drug war, just reaffirmed its commitment to lunacy by keeping cannabis as a Schedule 1 drug with “no currently accepted medical use.” This policy, having no basis in reality, guides the federal government’s attitude.
We could go on about the mountains of scientific evidence that have come out on the medical benefits of cannabis and its extracts, or the fact that the American Epilepsy Society considers CBD oil to have the greatest potential for treating epileptic seizures, or the fact that many veterans with PTSD find cannabis to be the only effective treatment, and so on.
While the feds were throwing people in cages for weed possession in its escalation of the war on drugs — based on false pretenses, racism and suppression of the antiwar movement — another part of the government was funding medical cannabis research the entire time.
For 50 years, the U.S. National institutes of Health (NIH) has been funding an Israeli cannabis researcher. Raphael Mechoulam, now 84, was the first person to isolate the structure of both tetrahydrocannabinol (THC) and cannabidiol (CBD), and was the first to test the medicinal properties of THC. 30 years later, Mechoulam and his team discovered that THC triggered what they called the endocannabinoid system.
This revolutionary figure in cannabis research was receiving $100,000 a year from the NIH, while drug agencies and police across the U.S. wrecked countless lives and seized billions from innocent people.
“It started in 1963, when Mechoulam applied for NIH funding and was told that cannabis research wasn’t of interest to the agency because marijuana wasn’t an “American problem,” recalls Mechoulam. “They told me to let them know when I have something more relevant to the U.S.” A year later, Mechoulam received another call from the same official. A U.S. senator, whose name the official withheld from Mechoulam, had caught his son smoking weed. The senator had asked the NIH what e [...]